Sanchita Ghosh, Ph.D.

Sanchita P. Ghosh, Ph.D.

Name: Sanchita P. Ghosh, Ph.D.

USU Department of Primary Appointment: 
Pharmacology & Molecular Therapeutics
Title: 
Senior Principal Investigator, Adjunct Assistant Professor
Faculty Rank: 
Assistant Professor
Location: 
Uniformed Services University of the Health Sciences, Bethesda, MD

Research Interests:
Screening and development of medical countermeasures against acute radiation syndrome in murine model
Protect mice from radiation-induced hematopoietic and gastrointestinal injury, mechanism of action, and delayed effects from acute radiation exposure

Office Phone: 
(301) 295-1945

Education

2005-2009: Research Investigator (Henry M. Jackson Foundation), Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
2002-2005: Research Fellow, National Institute of Deafness and other Communications Disorder (NIDCD), NIH, Bethesda, USA.
1998-2000: Assistant Professor, Birla Institute Of Technology and Science, India.
1990-1994: Post Doctoral Fellow, Kent State University, Kent, Ohio, USA.
1990: Ph.D., Indian Association of Cultivation of Science, Kolkata, India.

Biography

The primary research interests of Dr. Ghosh’s laboratory are to screen and develop medical countermeasures for acute radiation syndrome (ARS) in murine model following guidelines established by the US FDA Animal Rule. Her focus on the development of drugs and treatment approaches are designed to prevent, mitigate, or reverse health damage resulting from exposure to ionizing radiation. The potential for exposure to harmful doses of ionizing radiation exists in a wide variety of scenarios including accidents in nuclear facilities as well as nuclear detonation. Her effort is to identify radiation countermeasures / drugs that belong to various classes such as antioxidants/immunostimulants, growth factors, or cellular products, that can reconstitute the immune system and/or overcome reactive oxygen species-induced biological changes in in vivo animal models. She uses a mouse model to screen various countermeasures exposed to γ-irradiation in AFRRI’s unique pool-type Cobalt 60 facility. Over the years, she has served as Principal Investigator in the Radiation Countermeasure Program with financial support from DTRA, DMRDP, JPC-7, NIAID-AFRRI Inter Agency Agreement (IAA), and intramural grants. She also serves as the Chair of the AFRRI Intramural Screening Program.
Her laboratory has extensive experience in studying the hematopoietic and gastrointestinal ARS following total-body and partial-body irradiation using murine model, and the effects of various radiation countermeasures on injury and recovery. To date, she has evaluated over 30 different compounds/drugs in the mouse model through material transfer agreement. Out of these candidates, 4 candidates emerged as promising countermeasures both as a prophylactic radiation countermeasure as well as a mitigator in the murine model. Her laboratory has identified a list of time-informed critical markers and mechanisms of significant translational potential in the context of a radiation exposure event using serum miRNAs and metabolites. She collaborates with academic institutions, DoD laboratories, and corporate collaborators in US as well as overseas. In summary, She has accomplished various research projects in AFRRI (Extramural and Intramural) which involves developing countermeasures in mouse models, developing partial body irradiated (gut and lung specific) mouse models in SARRP, studying radiation responses in biofluids and tissues from irradiated mice from total body as well as partial body irradiated (gut and lung specific), differential expression of microRNA/metabolites in mouse tissues after radiation.

Representative publications, projects, and/or deployments

  • 2009-Present: Research Biologist and Senior Principal Investigator, Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
  • Drug Screening for Radiation Mitigation Efficacy. Biomedical Advanced Research and Development Authority (BARDA), National Institute of Allergy and Infectious Diseases (NIAID), 9/30/2015 – 8/30/2020 (Open ended, yearly renewal expected every year), budget for: FY20 $573K.
  • Screening Radiation Countermeasures in Laboratory Mice, AFRRI Intramural funding 10/01/2009 – 8/30/2021 (Open ended, yearly renewal expected every year), budget for: FY20 $150K.
  • Development of thrombopoietin mimetic (TPOm) as a promising radiation countermeasure, Congressionally Directed Medical Research Programs/Joint Program Committee 7 (CDMRP/JPC7), ~$1.2 M, 05/01/2017-05/31/21.
  • Evaluation of the IGF-1/eNOS pathway as a moderator of radiation sensitivity, National Institute of Allergy and Infectious Diseases (NIAID), $581K, 9/30/2016 – 8/30/2021.
  • Development of thrombopoietin mimetic (TPOm) as a mitigator against Radiation-induced endovascular injuries. National Institute of Allergy and Infectious Diseases (NIAID), $750K, 06/01/2017 – 5/31/2022.
  • Studying Delayed Effects of Acute Radiation Exposure in a mouse and minipig model (6.2), $225K, 10/01/2019 – 09/30/2022.
  • Circulating MicroRNAs as Radiation Biodosimeters: Evaluation of Organ Responses. Joint Program Committee-7, $900K, 4/24/2020 – 4/23/2023.
  • May 2020: Winner of Received Radiobiology Research Award, Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

Bibliography

  • Sharma NK, Holmes-Hampton GP, Kumar VP, Biswas S, Wuddie K, Stone S, Aschenake Z, Wilkins WL, Fam CM, Cox GN, Ghosh SP. (2020) “Delayed effects of acute whole body lethal radiation exposure in mice pre-treated with BBT-059”. Scientific Reports, doi:10.1038/s41598-020-63818-7.
  • Sharma NK, Stone S, Kumar VP, Biswas S, Aghdam S, Holmes-Hampton GP, Fam CM, Cox GN, Ghosh, SP. (2019) “Mitochondrial degeneration and autophagy associated with delayed effects of radiation in mouse brain”. Front. Aging Neurosci., doi:10.3389/fnagi.2019.00357.
  • Satyamitra M, Cary L, Dunn D, Holmes-Hampton GP, Thomas LJ, and Ghosh SP. (2020) “CDX-301: a novel medical countermeasure for hematopoietic acute radiation syndrome in mice”. doi:10.1038/s41598-020-58186-1
  • Chakraborty N, Gautam A, Holmes-Hampton GP, Kumar VP, Biswas S, Kumar R, Hamad D, Dimitrov G, Olabisi AO, Hammamieh R, and Ghosh SP. (2020) “microRNA and Metabolite Signatures Linked to Early Consequences of Lethal Radiation”. doi:10.1038/s41598-020-62255-w.
  • Pathak R, Kumar VP, Hauer-Jensen M, and Ghosh SP. (2019) “Enhanced survival in mice exposed to ionizing radiation by combination of gamma-tocotrienol and simvastatin”. Military Medicine, 184, 3/4:644. doi: 10.1093/milmed/usy408.
  • Cheema AK, Byrum SD, Altadill T, Kumar VP, Biswas S, Balgley BM, Hauer-Jensen M, Tackett AJ, Ghosh SP. (2018) “Proteomic changes in mouse spleen following radiation injury and its modulation by gamma-tocotrienol”. Radiat Res, doi: 10.1667/RR15008.1.
  • Kumar VP, Biswas S., Sharma NK, Stone S, Fam CM, Cox GN, and Ghosh SP. (2018) “PEGylated IL-11 (BBT-059), a novel radiation countermeasure for hematopoietic acute radiation syndrome”. Health Phys. 115(1): 65–76. doi:10.1097/HP.0000000000000841.
  • Satyamitra M, Kumar VP, Biswas S, Cary L, Dickson L, and Ghosh SP. (2017) “Impact of abbreviated filgrastim schedule on survival and hematopoietic recovery post-irradiation in four mouse strains with different radiosensitivity”. Radiat Res., 187(6):659-671. doi: 10.1667/RR14555.1.
  • Ghosh SP, Kulkarni S, Hieber K, Toles R, Romanyukha L, Kao T-C, Hauer-Jensen M, and Kumar KS. (2009) “Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector”. Int J Radiat Biol. 85:598-606. https://doi.org/10.1080/09553000902985128.
  • Ghosh SP, Perkins MW, Hieber K, Kulkarni s, Kao T-C, Reddy EP, Reddy MVR, Maniar M, Seed T, and Kumar KS. (2009) “Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms”. Radiat Res. 171:173-179. https://doi.org/10.1667/RR1367.1